DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2019 của Esperion Therapeutics Inc

Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products include ETC-1002, an oral molecule therapy that is in Phase 2b clinical trials to treat patients with hypercholesterolemia, as well as to lower levels of LDL-cholesterol, and avoid various side effects associated with LDL-cholesterol lowering therapies.

TÊN CÔNG TY / COMPANY
Esperion Therapeutics Inc

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
ESPR

KỲ BÁO CÁO
2019

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare